Theravance Biopharma, Inc. (FRA:0TB)
Germany · Delayed Price · Currency is EUR 17.10
+0.10 (0.59%)
At close: Nov 28, 2025
Theravance Biopharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 29.34 | -56.42 | -55.19 | 872.13 | -199.43 | -278.02 | Upgrade |
Depreciation & Amortization | 5.61 | 6.12 | 6.15 | 7.02 | 8.6 | 6.97 | Upgrade |
Loss (Gain) From Sale of Assets | 0.2 | 0.03 | 1.35 | -2.72 | 0.04 | - | Upgrade |
Asset Writedown & Restructuring Costs | - | 4.51 | - | - | - | - | Upgrade |
Loss (Gain) From Sale of Investments | -2.3 | -2.51 | -1.9 | - | - | - | Upgrade |
Stock-Based Compensation | 19.82 | 21.39 | 25.37 | 39.73 | 62.06 | 62.98 | Upgrade |
Other Operating Activities | -15.71 | -5.03 | 5.56 | -960.95 | -67.5 | -16.9 | Upgrade |
Change in Accounts Receivable | -1.42 | -0.97 | -0.69 | -2.72 | 1.8 | 6.13 | Upgrade |
Change in Accounts Payable | 0.76 | 0.75 | 0.01 | -1.61 | -3.53 | 3.66 | Upgrade |
Change in Unearned Revenue | - | - | -0.22 | -0.19 | -11.46 | -26.47 | Upgrade |
Change in Income Taxes | 5.82 | 9.91 | 1.1 | 63.95 | -0.19 | -8.54 | Upgrade |
Change in Other Net Operating Assets | 201.58 | 10.67 | -8.54 | -17.08 | -26.17 | -12.56 | Upgrade |
Operating Cash Flow | 243.7 | -11.54 | -27 | -186.99 | -207.86 | -250.4 | Upgrade |
Capital Expenditures | -0.22 | -0.33 | -2.49 | -0.57 | -3.41 | -6.62 | Upgrade |
Sale of Property, Plant & Equipment | - | - | 1.51 | 4.58 | 0.01 | 0.06 | Upgrade |
Investment in Securities | -87.67 | 14.91 | -31.72 | 54.87 | 127.89 | 17.27 | Upgrade |
Other Investing Activities | -2.29 | -2.29 | - | 1,095 | - | - | Upgrade |
Investing Cash Flow | -90.19 | 12.28 | -32.7 | 1,154 | 124.49 | 10.72 | Upgrade |
Long-Term Debt Issued | - | - | - | - | - | 380 | Upgrade |
Long-Term Debt Repaid | - | - | - | -631.6 | -10.73 | -235.35 | Upgrade |
Net Debt Issued (Repaid) | - | - | - | -631.6 | -10.73 | 144.65 | Upgrade |
Issuance of Common Stock | 0.46 | 0.61 | 0.62 | 0.8 | 111.65 | 144.98 | Upgrade |
Repurchase of Common Stock | -2.58 | -3.1 | -199.55 | -132.28 | -9.06 | -9.75 | Upgrade |
Other Financing Activities | - | - | - | 4.28 | - | -16.8 | Upgrade |
Financing Cash Flow | -2.12 | -2.5 | -198.93 | -758.81 | 91.86 | 263.09 | Upgrade |
Net Cash Flow | 151.4 | -1.75 | -258.63 | 208.21 | 8.5 | 23.4 | Upgrade |
Free Cash Flow | 243.48 | -11.87 | -29.49 | -187.56 | -211.26 | -257.02 | Upgrade |
Free Cash Flow Margin | 303.11% | -18.43% | -51.35% | -365.29% | -381.96% | -357.68% | Upgrade |
Free Cash Flow Per Share | 4.82 | -0.24 | -0.53 | -2.55 | -3.04 | -4.12 | Upgrade |
Cash Interest Paid | - | - | - | 22.24 | 39.03 | 24.02 | Upgrade |
Cash Income Tax Paid | 21.77 | 0.11 | 0.02 | 117.97 | -4.09 | 0.01 | Upgrade |
Levered Free Cash Flow | 10.48 | -42 | -12.22 | 24 | -115.85 | -170.49 | Upgrade |
Unlevered Free Cash Flow | 12.06 | -40.41 | -10.75 | 27.98 | -110.5 | -165.15 | Upgrade |
Change in Working Capital | 206.74 | 20.36 | -8.34 | 42.35 | -39.55 | -37.78 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.